Adding quantitative muscle MRI to the FSHD clinical trial toolbox

Mul K, Vincenten SCC, Voermans NC, Lemmers RJLF, van der Vliet PJ, van der Maarel SM, Padberg GW, Horlings CGC, van Engelen BGM 
Neurology. 2017. 14;89(20):2057-2065.
 
Assessment from a cohort of 140 patients with facioscapulohumeral muscular dystrophy (FSHD) of correlation between quantitative MRI and MFM, FSHD clinical score, Ricci score, and 6-minute walking test.
The mean fat fraction of the total leg musculature correlated highly with the MFM (correlation coefficient of -0.845).

PubMed link

Keywords : Facioscapulohumeral muscular dystrophy, quantitative MRI

Articles dans les revues scientifiques

Protocol for a phase II, monocentre, double-blind, placebo-controlled, cross-over trial to assess efficacy of pyridostigmine in patients with spinal muscular atrophy types 2-4 (SPACE trial)

Stam M, Wadman RI, Wijngaarde CA, Bartels B, Asselman FL, Otto LAM, Goedee HS, Habets LE, de Groot JF, Schoenmakers MAGC, Cuppen I, van den Berg LH, van der Pol WL. BMJ Open. 2018. 30;8(7):e019932.  Protocol of the "SPACE" in wich MFM is used as an outcome measure....

read more